UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Identification and characterization of CYP3A420, a novel rare CYP3A4 allele without functional activity

Clinical pharmacology and therapeutics, 2006-04, Vol.79 (4), p.339-349

2006

Volltextzugriff (PDF)

PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY

Hematological oncology, 2019-06, Vol.37 (S2), p.235-237

2019

Volltextzugriff (PDF)

OP-09 Pharmacokinetic characteristics of the new treatment combination of sorafenib and resminostat, a novel histone deacetylase (HDAC) inhibitor, in patients with advanced hepatocellular carcinoma (HCC): The SHELTER study

Digestive and liver disease, 2013-04, Vol.45, p.S251-S251

2013

Volltextzugriff (PDF)

Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis

Blood advances, 2020-11, Vol.4 (22), p.5773-5784

2020

Volltextzugriff (PDF)

542 Centralised analysis of phase I ECG dataset of resminostat, a new oral histone deacetylase inhibitor (HDACi)

European journal of cancer supplements, 2010, Vol.8 (7), p.172-172

2010

Volltextzugriff (PDF)

540 Clinical phase II development of resminostat, a novel HDAC inhibitor

European journal of cancer supplements, 2010, Vol.8 (7), p.172-172

2010

Volltextzugriff (PDF)

Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects

International journal of clinical pharmacology and therapeutics, 2006-11, Vol.44 (11), p.572-579

2006

Volltextzugriff (PDF)

The pharmacokinetics of a 1-h paclitaxel infusion

Cancer chemotherapy and pharmacology, 2000, Vol.45 (6), p.463-470

2000

Volltextzugriff (PDF)

1255 Clinical and preclinical development of 4SC-201, a new oral histone deacetylase (HDAC) inhibitor

European journal of cancer supplements, 2009, Vol.7 (2), p.137-137

2009

Volltextzugriff (PDF)

Pharmacokinetics of the selective PDE4 inhibitor Roflumilast and its active metabolite Roflumilast N-oxide are not affected by concomitant budesonide, salbutamol, or erythromycin1

Journal of allergy and clinical immunology, 2004-02, Vol.113 (2), p.S222

HAUNS, B

2004

Volltextzugriff (PDF)

Phase II Study of Combined 5-Fluorouracil/ Ginkgo biloba Extract (GBE 761 ONC) Therapy in 5-Fluorouracil Pretreated Patients with Advanced Colorectal Cancer

Phytotherapy research, 2001-02, Vol.15 (1), p.34-38

2001

Volltextzugriff (PDF)

Pharmacokinetics of the selective PDE4 inhibitor Roflumilast and its active metabolite Roflumilast N-oxide are not affected by concomitant budesonide, salbutamol, or erythromycin

Journal of allergy and clinical immunology, 2004-02, Vol.113 (2), p.S222-S222

2004

Volltextzugriff (PDF)

Pharmacokinetics and safety of Roflumilast, a once-daily, oral, selective PDE4 inhibitor, and its active metabolite Roflumilast N-oxide in healthy subjects

Journal of allergy and clinical immunology, 2004-02, Vol.113 (2), p.S222-S222

2004

Volltextzugriff (PDF)

Dose-Proportional Intraindividual Single- and Repeated-Dose Pharmacokinetics of Roflumilast, an Oral, Once-Daily Phosphodiesterase 4 Inhibitor

Journal of clinical pharmacology, 2007-01, Vol.47 (1), p.26-36

2007

Volltextzugriff (PDF)

Central ECG analysis of resminostat, a new oral histone deacetylase inhibitor (HDACi), in clinical development as anticancer compound

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e13609-e13609

2010

Volltextzugriff (PDF)

393 POSTER First-in-man Phase I trial of BYK408740, an oral histone deacetylase inhibitor, in patients with advanced malignancies

European journal of cancer supplements, 2008, Vol.6 (12), p.123-124

2008

Volltextzugriff (PDF)

Pharmakokinetik von Roflumilast bei gleichzeitiger oraler Gabe von Inhibitoren und Induktoren des Cytochrom (CYP) P450 Systems

Pneumologie (Stuttgart, Germany), 2010, Vol.64 (S 03)

2010

Volltextzugriff (PDF)

Pharmakokinetik des selektiven Phosphodiesterease 4 (PDE4)-Inhibitors Roflumilast

Pneumologie (Stuttgart, Germany), 2010, Vol.64 (S 03)

2010

Volltextzugriff (PDF)

PF614 PATIENT‐REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB‐RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)

HemaSphere, 2019-06, Vol.3 (S1), p.260-261

2019

Volltextzugriff (PDF)

Investigation of a Potential Food Effect on the Pharmacokinetics of Roflumilast, an Oral, Once-Daily Phosphodiesterase 4 Inhibitor, in Healthy Subjects

Journal of clinical pharmacology, 2006-10, Vol.46 (10), p.1146-1153

2006

Volltextzugriff (PDF)

Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics

Seminars in oncology, 1997-12, Vol.24 (6 Suppl 19), p.S19

1997

Volltextzugriff (PDF)

Clinical update on the SHELTER study: A phase I/II trial of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2011-02, Vol.29 (4_suppl), p.275-275

2011

Volltextzugriff (PDF)

Clinical phase I study with one-hour paclitaxel infusion

Annals of oncology, 1998-05, Vol.9 (5), p.569-572

1998

Volltextzugriff (PDF)

Clinical update on a phase I/II trial of HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): The SHELTER study

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e13603-e13603

2011

Volltextzugriff (PDF)

First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC): The SHELTER study

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e14661-e14661

2010

Volltextzugriff (PDF)

1 – 25 von 67

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(53)

Publikationsform

Sprache

Englisch
(62)
Deutsch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Humans
(18)
Life Sciences & Biomedicine
(17)
Female
(14)
Male
(14)
Adult
(10)
Biological And Medical Sciences
(9)
Medical Sciences
(8)
Middle Aged
(7)
Pharmacology & Pharmacy
(7)
Pharmacology. Drug Treatments
(6)
Antineoplastic Agents
(5)
Adolescent
(4)
Aged
(4)
Aminopyridines - Blood
(4)
Aminopyridines - Pharmacokinetics
(4)
Antineoplastic Agents, Phytogenic - Administration & Dosage
(4)
Benzamides - Blood
(4)
Benzamides - Pharmacokinetics
(4)
Chemotherapy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Identification and characterization of CYP3A420, a novel rare CYP3A4 allele without functional activity

PATIENT‐REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB‐RITUXIMAB IN THE INNOVATE STUDY

OP-09 Pharmacokinetic characteristics of the new treatment combination of sorafenib and resminostat, a novel histone deacetylase (HDAC) inhibitor, in patients with advanced hepatocellular carcinoma (HCC): The SHELTER study

Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis

542 Centralised analysis of phase I ECG dataset of resminostat, a new oral histone deacetylase inhibitor (HDACi)

540 Clinical phase II development of resminostat, a novel HDAC inhibitor

Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects

The pharmacokinetics of a 1-h paclitaxel infusion

1255 Clinical and preclinical development of 4SC-201, a new oral histone deacetylase (HDAC) inhibitor

Pharmacokinetics of the selective PDE4 inhibitor Roflumilast and its active metabolite Roflumilast N-oxide are not affected by concomitant budesonide, salbutamol, or erythromycin1

Phase II Study of Combined 5-Fluorouracil/ Ginkgo biloba Extract (GBE 761 ONC) Therapy in 5-Fluorouracil Pretreated Patients with Advanced Colorectal Cancer

Pharmacokinetics of the selective PDE4 inhibitor Roflumilast and its active metabolite Roflumilast N-oxide are not affected by concomitant budesonide, salbutamol, or erythromycin

Pharmacokinetics and safety of Roflumilast, a once-daily, oral, selective PDE4 inhibitor, and its active metabolite Roflumilast N-oxide in healthy subjects

Dose-Proportional Intraindividual Single- and Repeated-Dose Pharmacokinetics of Roflumilast, an Oral, Once-Daily Phosphodiesterase 4 Inhibitor

Central ECG analysis of resminostat, a new oral histone deacetylase inhibitor (HDACi), in clinical development as anticancer compound

393 POSTER First-in-man Phase I trial of BYK408740, an oral histone deacetylase inhibitor, in patients with advanced malignancies

Pharmakokinetik von Roflumilast bei gleichzeitiger oraler Gabe von Inhibitoren und Induktoren des Cytochrom (CYP) P450 Systems

Pharmakokinetik des selektiven Phosphodiesterease 4 (PDE4)-Inhibitors Roflumilast

PF614 PATIENT‐REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB‐RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)

Investigation of a Potential Food Effect on the Pharmacokinetics of Roflumilast, an Oral, Once-Daily Phosphodiesterase 4 Inhibitor, in Healthy Subjects

Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics

Clinical update on the SHELTER study: A phase I/II trial of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC)

Clinical phase I study with one-hour paclitaxel infusion

Clinical update on a phase I/II trial of HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): The SHELTER study

First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC): The SHELTER study

Suchergebnisse filtern